医学と薬学　79/6　2022年6月号

出版社： 自然科学社
発行日： 2022-05-27
分野： 薬学  >  雑誌
ISSN： 03893898
雑誌名：
特集： 膵癌治療における薬物療法
電子書籍版： 2022-05-27 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

2,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

購入する

目次

  • 特集　膵癌治療における薬物療法

    序文
    膵癌治療における薬物療法の歴史
    遠隔転移を伴う切除不能膵癌に対する薬物治療
    膵癌の術後補助化学療法
    切除可能膵癌に対する術前化学療法
    膵癌治療における免疫チェックポイント阻害薬の可能性
    遺伝子異常に起因する膵癌に対する薬物治療の可能性
    膵癌の支持・緩和療法における薬物療法

    Diagnosis
    　全自動化学発光酵素免疫測定装置ルミパルス®L2400による
    　　TgAb，TPOAbおよびTRAb検査試薬の評価
    　ユーロピウム粒子を用いた蛍光イムノクロマト法による
    　　SARS-CoV-2抗原定性検査試薬「Exdia EKテストCOVID-19 Ag」の性能評価
    　ECLIA法による抗p53抗体測定試薬「エクルーシス試薬Anti-p53」の性能評価
    　生化学自動分析装置JCA-BM9130を用いた新型コロナウイルス抗体検査試薬
    　 「SARS-CoV-2 UTAB FS」の有用性の検討

    Cosmetic
    　オールインワン化粧品「シズカホワイトゲル」の加齢肌に対する美白効果
    　　―ヒト臨床比較対照試験―
    　リパーゼ配合男性用洗顔ジェルの皮脂洗浄の効果

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 膵癌治療における薬物療法】

P.753 掲載の参考文献
1) 国立研究開発法人国立がん研究センターがん対策情報センター : がん登録・統計. http://ganjoho.jp/reg_stat/statistics/index.html
 
2) 日本膵臓学会膵癌診療ガイドライン改訂委員会 編 : 膵癌診療ガイドライン 2019年版, 金原出版, 東京, 2019.
 
3) Neoptolemos JP, Stocken DD, Friess H, et al : A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (12) : 1200-1210, 2004.
PubMed
4) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 310 (14) : 1473-1481, 2013.
PubMed
5) Uesaka K, Boku N, Fukutomi A, et al : Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388 (10041) : 248-257, 2016.
PubMed
6) Neoptolemos JP, Palmer DH, Ghaneh P, et al : Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial. Lancet 389 (10073) : 1011-1024, 2017.
PubMed
7) Conroy T, Hammel P, Hebbar M, et al : FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 379 (25) : 2395-2406, 2018.
PubMed
8) Tempero MA, Reni M, Riess H, et al : APACT : Phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. J Clin Oncol 37 (suppl) : abstr 4000, 2019.
 
9) Satoi S, Unno M, Motoi F, et al : The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial ; Prep-02/JSAP-05). J Clin Oncol 37 (suppl) : abstr 4126, 2019.
 
10) Moertel CG, Childs DS, Jr., Reitemeier RJ, et al : Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 2 (7626) : 865-867, 1969.
PubMed
11) Moertel CG, Frytak S, Hahn RG, et al : Therapy of locally unresectable pancreatic carcinoma : a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil : The Gastrointestinal Tumor Study Group. Cancer 48 (8) : 1705-1710, 1981.
 
12) Cohen SJ, Dobelbower R, Jr., Lipsitz S, et al : A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas : Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 62 (5) : 1345-1350, 2005.
 
13) Klaassen DJ, MacIntyre JM, Catton GE, et al : Treatment of locally unresectable cancer of the stomach and pancreas : a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil-an Eastern Cooperative Oncology Group study. J Clin Oncol 3 (3) : 373-378, 1985.
 
14) Gastrointestinal Tumor Study Group : Treatment of locally unresectable carcinoma of the pancreas : comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 80 (10) : 751-755, 1988.
 
15) Ishii H, Furuse J, Boku N, et al : Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma : JCOG0506. Jpn J Clin Oncol 40 (6) : 573-579, 2010.
PubMed
16) Chauffert B, Mornex F, Bonnetain F, et al : Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 19 (9) : 1592-1599, 2008.
 
17) Loehrer PJ, Sr., Feng Y, Cardenes H, et al : Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer : an Eastern Cooperative Oncology Group trial. J Clin Oncol 29 (31) : 4105-4112, 2011.
 
18) Mukherjee S, Hurt CN, Bridgewater J, et al : Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP) : a multicentre, randomised, phase 2 trial. Lancet Oncol 14 (4) : 317-326, 2013.
 
19) Hammel P, Huguet F, van Laethem JL, et al : Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib : the LAP07 randomized clinical trial. JAMA 315 (17) : 1844-1853, 2016.
PubMed
20) Ioka T, Furuse J, Fukutomi A, et al : Randomized phase II study of chemoradiotherapy with versus without induction chemotherapy for locally advanced pancreatic cancer : Japan Clinical Oncology Group trial, JCOG1106. Jpn J Clin Oncol 51 (2) : 235-243, 2021.
PubMed
21) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19) : 1817-1825, 2011.
 
22) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (18) : 1691-1703, 2013.
PubMed
23) Suker M, Beumer BR, Sadot E, et al : FOLFIRINOX for locally advanced pancreatic cancer : a systematic review and patient-level meta-analysis. Lancet Oncol 17 (6) : 801-810, 2016.
PubMed
24) Philip PA, Lacy J, Portales F, et al : Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT) : a multicentre, open-label phase 2 study. Lancet Gastroenterol Hepatol 5 (3) : 285-294, 2020.
PubMed
25) Ozaka M, Ueno M, Ishii H, et al : Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407). 2021 ASCO Annual Meeting. J Clin Oncol 39 (suppl 15) : abstr 4017, 2021.
 
26) Burris HA 3rd, Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol 15 (6) : 2403-2413, 1997.
 
27) Moore MJ, Goldstein D, Hamm J, et al : Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 (15) : 1960-1966, 2007.
 
28) Ueno H, Ioka T, Ikeda M, et al : Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan : GEST Study. J Clin Oncol 31 (13) : 1640-1648, 2013.
PubMed
29) Okusaka T, Ikeda M, Fukutomi A, et al : Phase II study of FOLFIRINOX for metastatic chemotherapy-naive Japanese pancreatic cancer patients. Cancer Sci 105 (10) : 1321-1326, 2014.
PubMed
30) Ueno H, Ikeda M, Ueno M, et al : Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77 (3) : 595-603, 2016.
PubMed
31) Ozaka M, Ishii H, Sato T, et al : A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81 (6) : 1017-1023, 2018.
 
32) Pelzer U, Schwaner I, Stieler J, et al : Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer : a phase III-study from the German CONKO-study group. Eur J Cancer 47 (11) : 1676-1681, 2011.
 
33) Oettle H, Riess H, Stieler JM, et al : Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer : outcomes from the CONKO-003 trial. J Clin Oncol 32 (23) : 2423-2429, 2014.
 
34) Gill S, Ko YJ, Cripps C, et al : PANCREOX : A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. J Clin Oncol 34 (32) : 3914-3920, 2016.
PubMed
35) Wang-Gillam A, Li CP, Bodoky G, et al : Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1) : a global, randomised, open-label, phase 3 trial. Lancet 387 (10018) : 545-557, 2016.
PubMed
36) Ohkawa S, Okusaka T, Isayama H, et al : Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 112 (9) : 1428-1434, 2015.
 
37) Ioka T, Komatsu Y, Mizuno N, et al : Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 116 (4) : 464-471, 2017.
 
38) Ioka T, Ueno M, Ueno H, et al : TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer : a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer 106 : 78-88, 2019.
PubMed
39) Ueno M, Nakamori S, Sugimori K, et al : nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer : Randomized phase 2 trial in Japanese patients. Cancer Med 9 (24) : 9396-9408, 2020.
PubMed
40) Le DT, Durham JN, Smith KN, et al : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 (6349) : 409-413, 2017.
 
41) Marabelle A, Le DT, Ascierto PA, et al : Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer : results from the phase II KEYNOTE-158 Study. J Clin Oncol 38 (1) : 1-10, 2020.
PubMed
42) Doebele RC, Drilon A, Paz-Ares L, et al : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours : integrated analysis of three phase 1-2 trials. Lancet Oncol 21 (2) : 271-282, 2020.
PubMed
43) Laetsch TW, DuBois SG, Mascarenhas L, et al : Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions : phase 1 results from a multicentre, open-label, phase 1/2 study. Lancet Oncol 19 (5) : 705-714, 2018.
 
44) Golan T, Hammel P, Reni M, et al : Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381 (4) : 317-327, 2019.
PubMed
P.763 掲載の参考文献
1) Mizrahi JD, Surana R, Valle JW, et al : Pancreatic cancer. Lancet 395 : 2008-2020, 2020.
PubMed
2) Burris HA, Moore MJ, Andersen J, et al : Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer : a randomized trial. J Clin Oncol Official J Am Soc Clin Oncol 15 : 2403-2413, 1997.
 
3) Moore MJ, Goldstein D, Hamm J, et al : Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer : A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25 : 1960-1966, 2007.
 
4) Ueno H, Ioka T, Ikeda M, et al : Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan : GEST Study. J Clin Oncol 31 : 1640-1648, 2013.
PubMed
5) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer. New Engl J Medicine 364 : 1817-1825, 2011.
 
6) Okusaka T, Ikeda M, Fukutomi A, et al : Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Sci 105 : 1321-1326, 2014.
PubMed
7) Ozaka M, Ishii H, Sato T, et al : A phase II study of modified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. Cancer Chemoth Pharm 81 : 1017-1023, 2018.
 
8) Hoff DDV, Ervin T, Arena FP, et al : Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New Engl J Medicine 369 : 1691-1703, 2013.
 
9) Ueno H, Ikeda M, Ueno M, et al : Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemoth Pharm 77 : 595-603, 2016.
 
10) Pelzer U, Schwaner I, Stieler J, et al : Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer : A phase III-study from the German CONKO-study group. Eur J Cancer 47 : 1676-1681, 2011.
 
11) Oettle H, Riess H, Stieler JM, et al : Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer : Outcomes From the CONKO-003 Trial. J Clin Oncol Official J Am Soc Clin Oncol 32 : 2423-2429, 2014.
 
12) Gill S, Ko Y-J, Cripps C, et al : PANCREOX : A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. J Clin Oncol 34 : 3914-3920, 2016.
PubMed
13) Wang-Gillam A, Li C-P, Bodoky G, et al : Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1) : a global, randomised, open-label, phase 3 trial. Lancet 387 : 545-557, 2016.
PubMed
14) Ueno M, Nakamori S, Sugimori K, et al : nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer : Randomized phase 2 trial in Japanese patients. Cancer Med-us 9 : 9396-9408, 2020.
 
15) Ioka T, Ueno M, Ueno H, et al : TAS-118 (S-1 plus leucovorin) versus S-1 in patients with gemcitabine-refractory advanced pancreatic cancer : a randomised, open-label, phase 3 study (GRAPE trial). Eur J Cancer 106 : 78-88, 2019.
PubMed
16) Go S-I, Lee S-C, Bae WK, et al : Modified FOLFIRINOX versus S-1 as second-line chemotherapy in gemcitabine-failed metastatic pancreatic cancer patients : A randomised controlled trial (MPACA-3). Eur J Cancer 157 : 21-30, 2021.
PubMed
P.768 掲載の参考文献
1) Neoptolemos JP, Stocken DD, Friess H, et al : A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. N Engl J Med 350 (12) : 1200-1210, 2004.
PubMed
2) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 297 (3) : 267-277, 2007.
PubMed
3) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 310 (14) : 1473-1481, 2013.
PubMed
4) Ueno H, Kosuge T, Matsuyama Y, et al : A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer : Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 101 (6) : 908-915, 2009.
 
5) Neoptolemos JP, Stocken DD, Bassi C, et al : Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection : a randomized controlled trial. JAMA 304 (10) : 1073-1081, 2010.
PubMed
6) Uesaka K, Boku N, Fukutomi A, et al : Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388 (10041) : 248-257, 2016.
PubMed
7) Neoptolemos JP, Palmer DH, Ghaneh P, et al ; European Study Group for Pancreatic C. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial. Lancet 389 (10073) : 1011-1024, 2017.
 
8) Conroy T, Hammel P, Hebbar M, et al : FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 379 (25) : 2395-2406, 2018.
PubMed
9) Tempero MA, Reni M, Riess H, et al : APACT : phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma. J Clin Oncol 37 (15_suppl) : 4000, 2019.
 
10) Unno M, Motoi F, Matsuyama Y, et al : Randomized phase II/III tria l of neoad juvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol 37 (4 _suppl) : 189-189, 2019.
 
11) Inoue Y, Saiura A, Oba A, et al : Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer : Balancing Surgical and Oncological Safety. J Gastrointest Surg 23 (7) : 1373-1383, 2019.
PubMed
12) Jang JY, Kang MJ, Heo JS, et al : A prospective randomized controlled study comparing outcomes of standard resection and extended resection, including dissection of the nerve plexus and various lymph nodes, in patients with pancreatic head cancer. Ann Surg 259 (4) : 656-664, 2014.
PubMed
13) Nimura Y, Nagino M, Takao S, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19 (3) : 230-241, 2012.
 
14) Yamada S, Satoi S, Takami H, et al : Multicenter randomized phase II trial of prophylactic righthalf dissection of superior mesenteric artery nerve plexus in pancreatoduodenectomy for pancreatic head cancer. Ann Gastroenterol Surg 5 (1) : 111-118, 2021.
PubMed
15) Yabusaki N, Fujii T, Yamada S, et al : The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma-including the analysis of clinicopathological factors influencing relative dose intensity. Medicine (Baltimore) 95 (29) : e4282, 2016.
PubMed
P.775 掲載の参考文献
1) 国立がん研究センター : がん情報サービス. https://ganjoho.jp/reg_stat/statistics/stat/summary.html
 
2) Oettle H, Neuhaus P, Hochhaus A, et al : Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer : the CONKO-001 randomized trial. JAMA 310 (14) : 1473-1481, 2013.
PubMed
3) Yeo CJ, Cameron JL, Lillemoe KD, et al : Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2 : randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 236 (3) : 355-366, 2002.
 
4) Nimura Y, Nagino M, Takao S, et al : Standard versus extended lymphadenectomy in radical pancreatoduodenectomy for ductal adenocarcinoma of the head of the pancreas : long-term results of a Japanese multicenter randomized controlled trial. J Hepatobiliary Pancreat Sci 19 (3) : 230-241, 2012.
 
5) Jang JY, Kang JS, Han Y, et al : Long-term outcomes and recurrence patterns of standard versus extended pancreatectomy for pancreatic head cancer : a multicenter prospective randomized controlled study. J Hepatobiliary Pancreat Sci 24 (7) : 426-433, 2017.
PubMed
6) Jones RP, Psarelli EE, Jackson R, et al : Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma : A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. JAMA Surg 154 (11) : 1038-1048, 2019.
PubMed
7) Neoptolemos JP, Dunn JA, Stocken DD, et al : Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer : a randomised controlled trial. Lancet 358 (9293) : 1576-1585, 2001.
PubMed
8) Oettle H, Post S, Neuhaus P, et al : Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer : a randomized controlled trial. JAMA 297 (3) : 267-277, 2007.
PubMed
9) Neoptolemos JP, Moore MJ, Cox TF, et al : Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma : the ESPAC-3 periampullary cancer randomized trial. JAMA 308 (2) : 147-156, 2012.
PubMed
10) Uesaka K, Boku N, Fukutomi A, et al : Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer : a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet 388 (10041) : 248-257, 2016.
PubMed
11) Neoptolemos JP, Palmer DH, Ghaneh P, et al : Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4) : a multicentre, open-label, randomised, phase 3 trial. Lancet 389 (10073) : 1011-1024, 2017.
PubMed
12) Conroy T, Hammel P, Hebbar M, et al : FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 379 (25) : 2395-2406, 2018.
PubMed
13) 日本膵臓学会 膵癌診療ガイドライン改訂委員会 編 : RA3 膵癌の術後補助化学療法は推奨されるか? 膵癌診療ガイドライン 2019年版, pp.184-189, 金原出版, 東京, 2019.
 
14) Cancer of the Pancreas : ESMO Clinical Practice guidelines. eUpdate 15 March 2019 : New recommendations for pancreatic cancer. https://www.esmo.org/guidelines/gastrointestinal-cancers/pancreatic-cancer/eupdate-cancer-of-thepancreas-treatment-recommendations
 
15) NCCN Guidelines (R) Pancreatic Adenocarcinoma Version 2, 2021. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf
 
16) 元井冬彦, 海野倫明 : 術前治療時代の膵癌治療戦略. 胆と膵 40 (11) : 949-955, 2019.
Medical*Online
17) 日本膵臓学会 編 : 切除可能性分類. 膵癌取扱い規約 第7版, pp.48-53, 金原出版, 東京, 2020.
 
18) Matsumoto I, Murakami Y, Shinzeki M, et al : Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection : A multi-center retrospective study. Pancreatology Nov-Dec 15 (6) : 674-680, 2015.
PubMed
19) Motoi F, Murakami Y, Okada KI, et al : Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively Resected Pancreatic Adenocarcinoma. World J Surg 43 (2) : 634-641, 2019.
PubMed
20) Aoki S, Miyata H, Konno H, et al : Risk factors of serious postoperative complications after pancreaticoduodenectomy and risk calculators for predicting postoperative complications : a nationwide study of 17,564 patients in Japan. J Hepatobiliary Pancreat Sci 24 (5) : 243-251, 2017.
PubMed
21) Motoi F, Unno M : Neoadjuvant treatment for resectable pancreatic adenocarcinoma : What is the best protocol? Ann Gastroenterol Surg Feb 4 (2) : 100-108, 2020.
PubMed
22) Rea D, Tomlins A, Francis A : Time to stop operating on breast cancer patients with pathological complete response? Eur J Surg Oncol 39 (9) : 924-30, 2013.
PubMed
23) Palmer DH, Stocken DD, Hewitt H, et al : A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer : gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 14 (7) : 2088-2096, 2007.
PubMed
24) Motoi F, Unno M, Takahashi H, et al : Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer : project study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 21 (2) : 148-158, 2014.
PubMed
25) Motoi F, Satoi S, Honda G, et al : A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma : PREP-01 study. J Gastroenterol 54 (2) : 194-203, 2019.
PubMed
26) Motoi F, Kosuge T, Ueno H, et al : Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn J Clin Oncol 49 (2) : 190-194, 2019.
PubMed
27) Unno M, Motoi F, Matsuyama Y, et al : Randomized phase II/III tria l of neoad juvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). J Clin Oncol 37 (suppl 4) : abstr 189, 2019.
 
28) Satoi S, Unno M, Motoi F, et al : The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial ; Prep-02/JSAP-05). J Clin Oncol 37 (suppl) : abstr 4126, 2019.
 
29) 日本膵臓学会ホームページ : 膵癌診療ガイドライン 2019 P176-179 RA1 改訂. http://www.suizou.org/pdf/guide2019_P176-179.pdf
 
30) 日本膵臓学会 膵癌診療ガイドライン改訂委員会編 : B2 膵癌に対して動脈合併切除は推奨されるか? 膵癌診療ガイドライン 2019年版, pp.195-200, 金原出版, 東京, 2019.
 
31) Jang JY, Han Y, Lee H, et al : Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer : A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg 268 (2) : 215-222, 2018.
 
32) Versteijne E, Suker M, Groothuis K, et al : Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 38 (16) : 1763-1773, 2020.
 
33) Versteijne E, van Dam JL, Suker M, et al : Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer : Long-Term Results of the Dutch Randomized PREOPANC Trial. J Clin Oncol 27 : JCO2102233, 2022.
 
34) Golcher H, Brunner TB, Witzigmann H, et al : Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer : results of the first prospective randomized phase II trial. Strahlenther Onkol 191 : 7-16, 2015.
PubMed
35) Casadei R, Di Marco M, Ricci C, et al : Neoadjuvant chemoradiotherapy and surgery versus surgery alone in resectable pancreatic cancer : a single-center prospective, randomized, controlled trial which failed to achieve accrual targets. J Gastrointest Surg 19 : 1802-1812, 2015.
 
36) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 (19) : 1817-1825, 2011.
 
37) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369 (18) : 1691-1703, 2013.
PubMed
38) Ueno H, Ioka T, Ikeda M, et al : Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan : GEST study. J Clin Oncol 31 (13) : 1640-1648, 2013.
PubMed
39) Ahmad SA, Duong M, Sohal DPS, et al : Surgical Outcome Results From SWOG S1505 : A Randomized Clinical Trial of mFOLFIRINOX Versus Gemcitabine/Nab-paclitaxel for Perioperative Treatment of Resectable Pancreatic Ductal Adenocarcinoma. Ann Surg 272 (3) : 481-486, 2020.
PubMed
40) Janssen QP, van Dam JL, Bonsing BA, et al : Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial) : study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer 21 (1) : 300, 2021
PubMed
41) Yamada D, Kobayashi S, Takahashi H, et al : Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGOHBP-015). Trials 22 (1) : 568, 2021.
PubMed
42) Sohai D, Duong MT, Ahmad SA, et al : SWOG S1505 : Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA). J Clin Oncol 38 (suppl 15) abstr 4504, 2020.
 
43) Ludmir EB, Palta M, Willett CG, et al : Total neoadjuvant therapy for rectal cancer : An emerging option. Cancer 123 (9) : 1497-1506, 2017.
PubMed
44) Murphy JE, Wo JY, Ryan DP, et al : Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma : A Phase 2 Clinical Trial. JAMA Oncol 4 (7) : 963-969, 2018.
PubMed
45) Murphy JE, Wo JY, Ryan DP, et al : Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer : A Phase 2 Clinical Trial. JAMA Oncol 5 (7) : 1020-1027, 2019.
PubMed
46) Satoi S, Yamaue H, Kato K, et al : Role of adjuvant surgery for patients with initially unresectable pancreatic cancer with a long-term favorable response to non-surgical anti-cancer treatments : results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci 20 (6) : 590-600, 2013.
PubMed
47) Kim RY, Christians KK, Aldakkak M, et al : Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Ann Surg Oncol 28 (4) : 2246-2256, 2021.
PubMed
48) Motoi F : Overcoming acquired chemo-resistance to gemcitabine : implications from the perspective of multi-modal therapy including surgery for pancreatic cancer. Cancer Drug Resist 4 : 881-884, 2021.
PubMed
P.783 掲載の参考文献
1) Maleki Vareki S : High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer 6 (1) : 157, 2018.
PubMed
2) Martinez-Bosch N, Vinaixa J, Navarro P : Immune Evasion in Pancreatic Cancer : From Mechanisms to Therapy. Cancers (Basel) 10 (1) : 6, 2018
 
3) Marabelle A, Fakih M, Lopez J, et al : Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 21 (10) : 1353-1365, 2020.
PubMed
4) Marabelle A, Le DT, Ascierto PA, et al : Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer : Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38 (1) : 1-10, 2020.
PubMed
5) Chalmers ZR, Connelly CF, Fabrizio D, et al : Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med 9 (1) : 34, 2017.
PubMed
6) Balachandran VP, Beatty GL, Dougan SK : Broadening the Impact of Immunotherapy to Pancreatic Cancer : Challenges and Opportunities. Gastroenterology 156 (7) : 2056-2072, 2019.
PubMed
7) Royal RE, Levy C, Turner K, et al : Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother 33 (8) : 828-833, 2010.
PubMed
8) Brahmer JR, Tykodi SS, Chow LQ, et al : Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (26) : 2455-2465, 2012.
PubMed
9) Wainberg ZA, Hochster HS, Kim EJ, et al : Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Clin Cancer Res 26 (18) : 4814-4822. 2020.
PubMed
10) Ueno M, Morizane C, Ikeda M, et al : A phase II study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancer. J Clin Oncol 40 (4 _suppl) : 553-553, 2022.
 
11) Gotwals P, Cameron S, Cipolletta D, et al : Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer 17 (5) : 286-301, 2017.
PubMed
12) Homma Y, Taniguchi K, Murakami T, et al : Immunological impact of neoadjuvant chemoradiotherapy in patients with borderline resectable pancreatic ductal adenocarcinoma. Ann Surg Oncol 21 (2) : 670-676, 2014.
PubMed
13) Luke JJ, Lemons JM, Karrison TG, et al : Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36 (16) : 1611-1618, 2018.
PubMed
14) Zhu X, Cao Y, Liu W, et al : Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection : an open-label, randomised, controlled, phase 2 trial. Lancet Oncol 22 (8) : 1093-1102, 2021.
PubMed
P.788 掲載の参考文献
1) Biankin AV, Waddell N, Kassahn KS, et al : Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 491 : 399-405, 2012.
PubMed
2) Aguirre AJ, Nowak JA, Camarda ND, et al : Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov 8 : 1096-1111, 2018.
PubMed
3) Waddell N, Pajic M, Patch AM, et al : Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518 : 495-501, 2015.
PubMed
4) Campbell PJ, Getz G, Korbel JO, et al : Pan-cancer analysis of whole genomes. Nature 578 : 82-93, 2020.
PubMed
5) Hudson TJ, Anderson W, Aretz A, et al : International network of cancer genome projects. Nature 464 : 993-998, 2010.
 
6) Cancer Genome Atlas Research Network : Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455 : 1061-1068, 2008.
 
7) Druker BJ, Guilhot F, O'Brien SG, et al : Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia. N Engl J Med 355 : 2408-2417, 2006.
 
8) Bower H, Bjorkholm M, Dickman PW, et al : Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol 34 : 2851-2857, 2016.
PubMed
9) Rahib L, Smith BD, Aizenberg R, et al : Projecting cancer incidence and deaths to 2030 : The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74 : 2913-2921, 2014.
PubMed
10) Siegel RL, Miller KD, Jemal A : Cancer statistics, 2019. CA Cancer J Clin 69 : 7-34, 2019.
 
11) Conroy T, Desseigne F, Ychou, M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364 : 1817-1825, 2011.
PubMed
12) Von Hoff DD, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369, 1691-1703, 2013.
PubMed
13) Connor AA, Denroche RE, Jang GH, et al : Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncol 3 : 774-783, 2017.
PubMed
14) Chang DK, Grimmond SM, Biankin AV : Pancreatic cancer genomics. Curr Opin Genet Dev 24 : 74-81, 2014.
PubMed
15) Qian ZR, Rubinson DA, Nowak JA, et al : Association of Alterations in Main Driver Genes with Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol 4 : e173420, 2018.
PubMed
16) Singhi AD, George B, Greenbowe JR, et al : Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers. Gastroenterology 156 : 2242-2253.e4, 2019.
PubMed
17) The Cancer Genome Atlas Research Network : Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32 : 185-203.e13, 2017.
 
18) Dreyer SB, Chang DK, Bailey P, et al : Pancreatic Cancer Genomes : Implications for Clinical Management and Therapeutic Development. Clin Cancer Res 23 : 1638-1646, 2017.
PubMed
19) Jones S, Zhang X, Parsons DW, et al : Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 : 1801-1806, 2008.
PubMed
20) Feigin ME, Garvin T, Bailey P, et al : Recurrent noncoding regulatory mutations in pancreatic ductal adenocarcinoma. Nat Genet 49 : 825-833, 2017.
PubMed
21) Golan T, Hammel P, Reni M, et al : Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med 381 : 317-327, 2019.
PubMed
22) Le DT, Durham JN, Smith KN, et al : Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357 : 409-413, 2017.
 
23) Le DT, Uram JN, Wang H, et al : PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 372 : 2509-2520, 2015.
PubMed
24) Doebele RC, Drilon A, Paz-Ares, et al : Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours : Integrated analysis of three phase 1-2 trials. Lancet Oncol 21 : 271-282, 2020.
PubMed
25) Drilon A, Laetsch TW, Kummar S, et al : Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378 : 731-739, 2018.
PubMed
26) Schram AM, O'Reilly EM, Somwar R, et al : Abstract PR02 : Clinical proof of concept for MCLA-128, a bispecific HER2/3 antibody therapy, in NRG1 fusion-positive cancers. Mol Cancer Ther 18 : PR02, 2019.
 
27) Pishvaian MJ, Blais EM, Brody JR, et al : Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling : A retrospective analysis of the Know Your Tumor registry trial. Lancet Oncol 21 : 508-518, 2020.
PubMed
28) Chantrill LA, Nagrial AM, Watson C, et al : Precision Medicine for Advanced Pancreas Cancer : The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial. Clin Cancer Res 21 : 2029-2037, 2015.
PubMed
29) Biankin AV, Piantadosi S, Hollingsworth SJ : Patient-centric trials for therapeutic development in precision oncology. Nature 526 : 361-370, 2015.
PubMed
30) Alexandrov LB, Nik-Zainal S, Wedge DC, et al : Signatures of mutational processes in human cancer. Nature 500 : 415-421, 2013.
PubMed
31) Alexandrov LB, Kim J, Haradhvala NJ, et al : The repertoire of mutational signatures in human cancer. Nature 578 : 94-101, 2020.
PubMed
32) Bailey P, Chang DK, Nones K, et al : Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531 : 47-52, 2016.
PubMed
33) Davies H, Glodzik D, Morganella S, et al : HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nat Med 23 : 517-525, 2017.
PubMed
34) Harder J, Ihorst G, Heinemann V, et al : Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer 106 : 1033-1038, 2012.
PubMed
35) Chou A, Waddell N, Cowley MJ, et al : Clinical and molecular characterization of HER2 amplified-pancreatic cancer. Genome Med 5 : 78, 2013.
PubMed
36) Safran H, Iannitti D, Ramanathan R, et al : Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Investig 22 : 706-712, 2004.
 
37) Pilie PG, Gay CM, Byers LA, et al : PARP Inhibitors : Extending Benefit Beyond BRCA-Mutant Cancers. Clin. Cancer Res 25 : 3759-3771, 2019.
PubMed
38) de Bono J, Mateo J, Fizazi K, et al : Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 382 : 2091-2102, 2020.
PubMed
39) Trenner A, Sartori AA : Harnessing DNA Double-Strand Break Repair for Cancer Treatment. Front. Oncol 9 : 1388. 2019.
PubMed
40) Berger MF, Mardis ER : The emerging clinical relevance of genomics in cancer medicine. Nat Rev Clin Oncol 15 : 353-365, 2018.
PubMed
41) Ersek JL, Black LJ, Thompson MA, et al : Implementing Precision Medicine Programs and Clinical Trials in the Community-Based Oncology Practice : Barriers and Best Practices. Am Soc Clin Oncol Educ Book 38 : 188-196, 2018.
PubMed
42) Kitano M, Yoshida T, Itonaga M, et al : Impact of endoscopic ultrasonography on diagnosis of pancreatic cancer. J Gastroenterol 54 : 19-32, 2019.
 
43) Baek HW, Park MJ, Rhee YY, et al : Diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology of pancreatic lesions. J Pathol Transl Med 49 : 52-60, 2015.
PubMed
44) Cros J, Raffenne J, Couvelard A, et al : Tumor Heterogeneity in Pancreatic Adenocarcinoma. Pathobiology 85 : 64-71, 2018.
PubMed
45) Vietsch EE, Graham GT, McCutcheon JN, et al : Reprint of : Circulating cell-free DNA mutation patterns in early and late stage colon and pancreatic cancer. Cancer Genet 228-229 : 131-142, 2018.
 
46) Lowery MA, Jordan EJ, Basturk O, et al : Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma : Potential Actionability and Correlation with Clinical Phenotype. Clin Cancer Res 23 : 6094-6100, 2017.
PubMed
47) Pea A, Cheng L, Luchin C : Dissecting the molecular landscape of pancreatic cancer : Towards a precision medicine approach. Expert Rev Precis Med Drug Dev 4 : 113-119, 2019.
 
P.794 掲載の参考文献
1) 日本膵臓学会膵癌診療ガイドライン改訂委員会編 : 膵癌診療ガイドライン 2019年版. pp.66-67, 金原出版, 東京, 2019.
 
2) World Health Organization : WHO Guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. World Health Organization, Geneva, 2018. https://www.who.int/publications/i/item/9789241550390.
 
3) Bandieri E, Romero M, Ripamonti CI, et al : Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. J Clin Oncol 34 (5) : 436-442, 2016.
PubMed
4) 日本緩和医療学会 緩和医療ガイドライン統括委員会 : がん疼痛の薬物療法に関するガイドライン 2020年版. 金原出版株式会社, 東京, 2020.
 
5) Katakami N, Harada T, Murata T, et al : Randomized Phase III and Extension Studies of Naldemedine in Patients With Opioid-Induced Constipation and Cancer. J Clin Oncol 35 : 3859-3866, 2017.
 
6) Tsukuura H, Miyazaki M, Morita T, et al. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT) : A Randomized, Placebo-Controlled, Double-Blind Trial. Oncologist 23 : 367-374, 2018.
 
7) Arcidiacono PG, Calori G, Carrara S, et al : Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database Syst Rev 3 : 1-22, 2011.
 
8) Hendifar AE, Petzel MQB, Zimmers TA, et al : Pancreas Cancer-Associated Weight Loss. Oncologist 24 : 691-701, 2019.
PubMed
9) Fearon K, Strasser F, Anker SD, et al : Definition and classification of cancer cachexia : an international consensus. Lancet Oncol 12 : 489-495, 2011.
PubMed
10) Katakami N, Uchino J, Yokoyama T, et al : Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia : Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124 : 606-616, 2018.
PubMed

【Diagnosis】

P.805 掲載の参考文献
1) 坂井礼, 網野信行 : 甲状腺疾患の診断と検査. 医療と検査機器・試薬 37 (2) : 217-220, 2014.
Medical*Online
2) 日高洋 : 甲状腺. 標準臨床検査医学 (高木康, 山田俊幸, 編), 第4版, 105-111, 医学書院, 東京, 2013.
 
3) 矢野美沙紀, 村上司, 他 : 化学発光酵素免疫測定法によるルミパルスプレスト(R) 甲状腺関連項目 (TSH, FT3, FT4, TgAb, TPOAb, TRAb) の性能評価. 医学と薬学77 (5) : 793-804, 2020.
 
P.816 掲載の参考文献
1) WHO : Coronavirus (COVID-19) Dashboard. https://covid19.who.int/
 
2) 日本感染症学会提言 : 今冬のインフルエンザとCOVID-19に備えて (2020年12月11日一部改訂)
 
3) 国立感染症研究所, 他 : 新型コロナウイルス感染症 (COVID-19) 病原体検査の指針 第5.1版
 
4) 国立感染症研究所, 他 : 病原体検出マニュアル 2019-nCoV Ver.2.9.1
 
5) Victor M Corman, Verena Claudia Haage, Tobias Bleicker, et al : Comparison of seven commercial SARS-CoV-2 rapid point-of-care antigen tests : a single-centre laboratory evaluation study. Lancet Microbe 2021 (2) : 311-319, 2021. DOI : https://doi.org/10.1016/S2666-5247(21)00056-2
 
6) Hiroyuki Tsukagoshi, Daisuke Shinoda, Mariko Saito, et al : Relationships between Viral Load and the Clinical course of COVID-19. Viruses 13 : 304-309, 2021.
PubMed
7) Elisabet Pujadas, Fayzan Chaudhry, Russell McBride, et al : SARS-CoV-2 viral load predicts COVID-19 mortality. The Lancet Respiratory Medicine 8 (9) : e70, 2020.
PubMed
P.823 掲載の参考文献
1) Crawford L V : Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30 : 403-408, 1982.
PubMed
2) Soussi T : p53 Antibodies in the sera of patients with various types of cancer : a review. Cancer Res 60 (7) : 1777-1788, 2000.
 
3) 島田英昭 : 血清p53抗体の測定によるがん診断の現状. 実験医学 35 (14) : 2362-2363, 2017.
Medical*Online
4) 竹田明彦, 小山勇, 島田英昭, 他 : 大腸癌に対する血清p53抗体測定の有用性と臨床的意義. 日本大腸肛門病会誌 60 : 198-204, 2007.
 
5) Yajima S, Suzuki T, Oshima Y, et al : New assay system Elecsys anti-p53 to detect serum anti-p53 antiboies in esophageal cancer patients and colorectal cancer patients : multi-institutional study. Ann Surg Oncol 28 (7) : 4007-4015, 2021.
 
6) エクルーシス(R) 試薬Anti-p53添付文書 https://www.info.pmda.go.jp/tgo/pack/30100EZX00026000_A_04_01/
 
7) Shimada H, Ochiai T, Nomura F, et al : Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors : a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97 : 682-689, 2003.
 
8) 衣笠哲史, 黒木政秀 : 癌胎児性抗原 (CEA). 日本臨牀 63 (増刊号 8) : 632-634, 2005.
 
9) 高橋祐, 江畑智希, 横山幸浩, 他 : CA19-9. 臨牀と研究 88 (8) : 949-951, 2011.
Medical*Online
P.832 掲載の参考文献
1) Wu, F, Zhao, S, Yu, B, et al : A new coronavirus associated with human respiratory disease in China. Nature 579 : 265-269, 2020.
 
2) WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarksat-the-media-briefing-on-covid-19---11-march-2020 [最終アクセス 2022年4月25日]
 
3) Dong E, Du H, Gardner L : An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 20 (5) : 533-534, 2020.
PubMed
4) Dagan N, Barda N, Kepten E, et al : BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med 384 (15) : 1412-1423, 2021.
 
5) Haas EJ, Angulo FJ, McLaughlin JM, et al : Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel : an observational study using national surveillance data. Lancet 397 (10287) : 1819-1829, 2021.
PubMed
6) Fujigaki H, Takemura M, Osawa M, et al : Reliability of serological tests for COVID-19 : comparison of three immunochromatography test kits for SARS-CoV-2 antibodies. Heliyon 6 (9) : e04929, 2020.
PubMed
7) Fujigaki H, Inaba M, Osawa M, et al : Comparative Analysis of Antigen-Specific Anti-SARS-CoV-2 Antibody Isotypes in COVID-19 Patients. J Immunol 206 (10) : 2393-2401, 2021.
PubMed
8) 藤垣英嗣, 竹村正男, 大澤道子, 他 : 全自動免疫生化学統合システムVITROSによるSARS-CoV-2 IgG抗体測定の基礎的検討. 医学と薬学 78 (3) : 281-288, 2021.
Medical*Online
9) Okamoto A, Fujigaki H, Iriyama C, et al : CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv. 2022 Jan 13 : bloodadvances.
 

【Cosmetic】

P.841 掲載の参考文献
1) 小出千春, 鈴木正, 水谷友紀, 他 : 日本人のしみ, そばかす, および美白化粧品等の実態に関するアンケート調査. 日本香粧品学会誌 30 (4) : 306-310, 2006.
 
2) 美白機能評価専門委員会 : <化粧品機能評価法ガイドライン> 新規効能取得のための医薬部外品美白機能評価試験ガイドライン. 日本香粧品学会誌 30 (4) : 333-337, 2006.
 
3) 抗老化機能評価専門委員会 : 新規効能取得のための抗シワ製品評価ガイドライン. 日本香粧品学会誌 30 (4) : 316-332, 2006.
 
4) 化粧品マーケディング要覧 2021 総括編. 富士経済グループ : 2021.
 
5) 柳井久江 : 4 Steps エクセル統計 第4版. オーエムエス出版, 東京, 2015.
 
6) 丹野修 : ビタミン類の新機能と化粧品への応用ナイアシンアミドの皮膚での新しい作用と化粧品への応用. フレグランスジャーナル 32 (2) : 35-39, 2004.
 
7) 日本化粧品工業会 : 化粧品統計. 化粧品と薬用化粧品. https://www.jcia.org/user/statistics/cosmeceuticals [最終アクセス 2022年4月23日]
 
8) 山田秀和 : 最近の女性に多いシワの種類に対する傾向と対策. COSMETIC STAGE 12 (2) : 1-7, 2017.
 
9) 金辰也 : 抗シワ化粧品の最新評価技術と製品開発. COSMETIC STAGE 12 (2) : 8-13, 2017.
 
10) 正木仁 : 機能性化粧品の展望. 薬剤学 75 (5) : 313-316, 2015.
Medical*Online
11) 中村睦子, 征也智美, 丹野修 : 官能特性用語「肌のなめらかさ」の解析-消費者意識・目視評価・皮膚生理パラメータ計測を用いて-. 日本化粧品技術者会誌 45 (4) : 306-314, 2011.
 
P.846 掲載の参考文献
1) 惣出兼征, 小川正, 松下雪郎 : トリグリセリドヒドロペルオキシドの酵素に対する影響とリパーゼによる分解. 日本農芸化学会誌 48 (8) : 473-475, 1974.
 
2) 塚田弘行, 高橋元次 : 皮脂分泌を測る. Dermatology Practice : 145-149, 2002.
 

書評

最近チェックした商品履歴

Loading...